Commitment and Contingencies - Additional Information (Details)

Commitment and Contingencies - Additional Information (Details)				3 Months Ended
	Sep. 08, 2020 Debtinstrument	Jan. 21, 2020 Debtinstrument	Nov. 18, 2015 USD ($)	Mar. 31, 2021 USD ($) $ / RNL
Royalty-Linked Notes
Other Commitments [Line Items]
Debt instrument outstanding portion \| $ / RNL				0.04
Debt instrument maturity date				Dec. 31, 2045
Debt instrument, aggregate potential payment capped rate				4,000
Pfizer License Agreement
Other Commitments [Line Items]
Potential future regulatory and sales milestone deferred payment period			2 years
Potential future regulatory and sales milestone deferred payment annual rate			8.00%
Pfizer License Agreement \| Royalty-Linked Notes
Other Commitments [Line Items]
Debt instrument outstanding portion \| $ / RNL				0.04
Debt instrument maturity date				Dec. 31, 2045
Debt instrument price per unit				$ 160.00
Debt instrument, aggregate potential payment capped rate				4,000
Pfizer License Agreement \| Royalty-Linked Notes \| Private Placement
Other Commitments [Line Items]
Number of debt instruments within each notes \| Debtinstrument		2,579,400
Pfizer License Agreement \| Royalty-Linked Notes \| Rights Offering
Other Commitments [Line Items]
Number of debt instruments within each notes \| Debtinstrument	11,000
Pfizer License Agreement \| Sulopenem
Other Commitments [Line Items]
Potential future regulatory and sales milestone payments due on approval of product			$ 20,000,000
Pfizer License Agreement \| Minimum
Other Commitments [Line Items]
Potential future regulatory milestone and sales milestone payments upon achievement of net sales			250,000,000
Pfizer License Agreement \| Maximum
Other Commitments [Line Items]
Potential future regulatory milestone and sales milestone payments upon achievement of net sales			$ 1,000,000,000

Quarterly report pursuant to Section 13 or 15(d)

Commitment and Contingencies - Additional Information (Details)